Login to Your Account

Pharma: Clinic Roundup

Monday, November 4, 2013

Sunovion Pharmaceuticals Inc., of Marlborough, Mass., published results from two pivotal trials supporting FDA approval of Latuda (lurasidone HCL) for major depressive episodes associated with bipolar I disorder in The American Journal of Psychiatry.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription